RPG Life Sciences Limited RPGLIFE NSEPHARMA
Company Overview
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
Why Investors Should Care
Generates a return on equity of 19.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 24.5%.
Net profit has compounded at 19.4% per year over the last five years.
Revenue has grown at a 11.3% CAGR over the past five years.
Trades at a P/E of 39.9, below the sector median of 40.0.
Maintains a net profit margin of 16.4%.
Recent Developments
- Mar 2026 Revenue of ₹702.00 Cr (+8.4% YoY); net profit ₹115.17 Cr.
- Trailing 12 Months Year-on-year growth — revenue +8.4%, earnings -37.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.3%, profit CAGR 19.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.31% |
| 1 Year: | 8.41% |
Compounded Profit Growth
| 5 Years: | 19.41% |
| 1 Year: | -37.15% |
Stock Price Performance
| 1 Year: | +10.46% |
| 6 Months: | +19.73% |
| 3 Months: | +47.58% |
| 1 Month: | +22.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)78.15 · Overbought
P/E of 39.87 is below the sector median of 39.97 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 24.5%.
- Compounding revenue at 11.3% over 5 years.
- Profit CAGR of 19.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 78 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RPGLIFE RPG Life Sciences Limited NSEPHARMA | 2,776.60 | 39.87 | ₹4,592.22 Cr | 0.84% | 24.52% | 19.03% | 11.31% | 19.41% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 172.71 Cr | 143.09 Cr | 168.92 Cr | 182.00 Cr | 180.03 Cr | 176.89 Cr |
| Cost of Revenue | - | 56.11 Cr | 48.72 Cr | 60.02 Cr | - | 64.90 Cr | 60.59 Cr |
| Gross Profit | - | 116.60 Cr | 94.37 Cr | 108.90 Cr | - | 115.13 Cr | 116.30 Cr |
| Operating Expenses | - | 72.90 Cr | 74.25 Cr | 78.57 Cr | 143.00 Cr | 80.75 Cr | 89.21 Cr |
| Operating Income | - | 43.70 Cr | 20.12 Cr | 30.33 Cr | 34.00 Cr | 34.38 Cr | 27.09 Cr |
| EBITDA | - | 52.47 Cr | 140.45 Cr | 40.70 Cr | 39.00 Cr | 34.75 Cr | 46.33 Cr |
| Interest Expense | - | 12.00 L | 18.00 L | 13.00 L | 0 | 25.00 L | 39.00 L |
| Pretax Income | - | 46.89 Cr | 134.90 Cr | 35.43 Cr | 49.00 Cr | 29.12 Cr | 40.20 Cr |
| Tax Provision | - | 11.96 Cr | 17.55 Cr | 9.14 Cr | 12.25 Cr | 6.99 Cr | 10.30 Cr |
| Net Income | - | 34.93 Cr | 117.35 Cr | 26.29 Cr | 37.00 Cr | 22.13 Cr | 29.90 Cr |
| Diluted EPS | - | 21.12 | 70.96 | 15.90 | 22.28 | 13.38 | 18.08 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 509.08 Cr | 577.48 Cr | 647.54 Cr | 702.00 Cr |
| Cost of Revenue | - | 178.23 Cr | 194.20 Cr | 223.92 Cr | 261.85 Cr |
| Gross Profit | - | 330.85 Cr | 383.28 Cr | 423.62 Cr | 440.15 Cr |
| Operating Expenses | - | 241.97 Cr | 271.21 Cr | 283.25 Cr | 313.46 Cr |
| Operating Income | - | 88.88 Cr | 112.07 Cr | 140.37 Cr | 126.69 Cr |
| EBITDA | - | 107.49 Cr | 135.36 Cr | 254.93 Cr | 176.57 Cr |
| Interest Expense | - | 31.00 L | 45.00 L | 62.00 L | 89.00 L |
| Pretax Income | - | 91.68 Cr | 117.84 Cr | 232.88 Cr | 154.20 Cr |
| Tax Provision | - | 24.04 Cr | 30.18 Cr | 49.64 Cr | 39.03 Cr |
| Net Income | - | 67.64 Cr | 87.66 Cr | 183.24 Cr | 115.17 Cr |
| Diluted EPS | - | 40.90 | 53.01 | 110.80 | 69.64 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 419.35 Cr | 512.87 Cr | 657.81 Cr | 793.16 Cr |
| Current Assets | - | 264.05 Cr | 298.09 Cr | 465.25 Cr | 559.48 Cr |
| Cash & Equivalents | - | 24.82 Cr | 19.72 Cr | 28.70 Cr | 150.46 Cr |
| Inventory | - | 95.05 Cr | 101.00 Cr | 92.98 Cr | 123.84 Cr |
| Receivables | - | 37.43 Cr | 49.13 Cr | 86.76 Cr | 116.68 Cr |
| Total Liabilities | - | 111.75 Cr | 138.02 Cr | 127.28 Cr | 187.81 Cr |
| Current Liabilities | - | 102.78 Cr | 130.96 Cr | 119.83 Cr | 160.57 Cr |
| Long Term Debt | 1.00 L | 0 | - | - | 13.33 Cr |
| Total Debt | 94.00 L | 1.00 L | 0 | - | 20.00 Cr |
| Total Equity | - | 307.60 Cr | 374.85 Cr | 530.53 Cr | 605.35 Cr |
| Shares Outstanding | - | 1.65 Cr | 1.65 Cr | 1.65 Cr | 1.65 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 90.82 Cr | 94.36 Cr | 77.86 Cr | 56.50 Cr |
| Investing Cash Flow | - | -105.81 Cr | -79.15 Cr | -41.80 Cr | 85.84 Cr |
| Financing Cash Flow | - | -17.12 Cr | -20.31 Cr | -27.08 Cr | -20.58 Cr |
| Capital Expenditure | - | -32.73 Cr | -69.23 Cr | -36.03 Cr | -65.36 Cr |
| Free Cash Flow | - | 58.09 Cr | 25.13 Cr | 41.83 Cr | -8.86 Cr |
| Net Change in Cash | - | -32.11 Cr | -5.10 Cr | 8.98 Cr | 121.76 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 65.0% | 66.4% | 65.4% | 62.7% |
| Operating Margin % | - | 17.5% | 19.4% | 21.7% | 18.0% |
| Net Margin % | - | 13.3% | 15.2% | 28.3% | 16.4% |
| ROE % | - | 22.0% | 23.4% | 34.5% | 19.0% |
| ROCE % | - | 28.1% | 29.3% | 26.1% | 20.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RPGLIFE
Why RPG Life Sciences' (NSE:RPGLIFE) Shaky Earnings Are Just The Beginning Of Its Problems - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOLXRUcWk3WG12TzllbmUxbU5FSVJJbi1yNm1UR0JLQ1Vta3pmSjJyWkJQM2RpYlRmTzg5Smc4eV84d1h5ZlNXQzFvcVBBbHRhN1hsaU1Jd0dodkxmVUVsWEs2M0tiV0xXSmRHR1VhSFJTaWRsdzN6THI3d012UUVXd3dZWmdHM2ROSGFRYz…
Q4 earnings, dividend news trigger 14% jump in RPG Life Sciences shares - Business Standard
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNcXVXR2QwdUhBaEdya0ZBWXE0NzhVMjJPX3ZGUU9xTEZOR0lZTDZfbTJsbC1hcDQ5MV94b05ON2lOa0V5bVVSel93YjVGOFFQY1NXTnBiU1VGM2wxekxtRERGeHpYQTJ5OE5VaWpSeGpNM1FIRjQ2Q3AwOVZNMWxIRWRWWWVNRGNydlVOb0…
RPG Life Sciences fixes record date July 9 for ₹24 dividend - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeTk1TTg2d0s5N0NnLVdJSmctSFVfdEdrOE5CWnZwUFpBMWxnNnZDSmE2eXVHVGRFSlBKalZwbUFXNWd2d09nQzFWdzkzZTZRTkRwMUpVTlIwbjBGWks2UnhOYWN6QkJYMzNvUVJVSG1LUzF6U3E4NXJPbDEwZzh2LVBYRFlBcVg3V2FuYn…
Buzzing Stocks: Bajaj Finance, RPG Life gain post Q4 earnings; Indian Hume up 5% on contract win - Moneycontrol.com
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPTklUR0U2cmp3dnhWUzdTZGQwTnI0M1gyOWRZc01ZWDVpQm5iWXVnMFEzVkVSNUhnTkJCdDlwVUMzeFRJODZzU3ZGM0tuWjlEZTV6ajVKVEt0SHVyYTNnZC03RDlhMXZUT09jVVROb3FXVXFlUlBURjRJcGgyQlVWRXJwRm9VNDQ1TzJ5RE…
RPG Life Sciences Q4 Results: Operating performance strong, base quarter one-off impacts profit - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxPcGRzaVRzWWplQTk0aUJBTmh1QzNGemhMX3R1bDNPZ1NFUEo5NTUwTkd5ZFk2SkoydGstNWdvcm9hdGJQTVQxSTJMZlExR0FscnVRbjE2dkd2M3hkWEFuWDkwV0hfa0xpUVlTMllnMW9fbHZaOVk3N2ozZ091UDQ2Zi1iQWtTdkhNUFI5Nj…
RPG Life Sciences tumbles over 10% as Q3 net profit declines 20% YoY - Business Standard
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNaEhqdVhyd282dUZxU1VsSUlaR2g4OFdjdkxkY1UwWVNENFQ2ZnBILWdpNndPSnZOSkpfVk1iZnZGc0tGekhXVnpMOGRZOHZtbVJPREJwUk9reUVrLWgxRF9pTFF1RElkdDVwSzdqWHI1VWJZNVJhcTR2RWszYXJwZnJ3NVFOT2IzTmdGQ1…
RPGLIFE — Frequently Asked Questions
What is the current share price of RPG Life Sciences Limited (RPGLIFE)?
As of 2026-07-15 09:52 IST, RPG Life Sciences Limited (RPGLIFE) trades at ₹2,776.60 on NSE. Its 52-week range is ₹1,726.93 to ₹2,856.90.
What is the market capitalisation of RPGLIFE?
RPG Life Sciences Limited (RPGLIFE) has a market capitalisation of ₹4,592.22 Cr on NSE.
What is the P/E ratio of RPGLIFE?
RPGLIFE trades at a trailing price-to-earnings (P/E) ratio of 39.87. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 7.71.
Does RPGLIFE pay a dividend?
RPG Life Sciences Limited (RPGLIFE) currently offers a dividend yield of 0.84%.
What is the return on equity (ROE) of RPGLIFE?
RPGLIFE has a return on equity (ROE) of 19.03%. Its return on capital employed (ROCE) is 24.52%.
Is RPGLIFE a good stock to buy?
This page provides a data-driven analysis of RPG Life Sciences Limited (RPGLIFE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.